

March 6, 2020

LSI Medience Corporation

**Accepting tests orders for novel coronavirus (SARS-CoV-2) test  
as it gets listed for insurance reimbursement**

**Start from March 6**

LSI Medience Corporation (head office: Chiyoda-ku, Tokyo; President: Haruo Watanabe), a subsidiary of PHC Holdings Corporation (headquarters: Minato-ku, Tokyo; President & CEO: Michael Kloss) announced today the start of the insurance reimbursed novel coronavirus testing (SARS-CoV-2 nucleic acid detection, “the test” hereinafter) as of March 6.

The test will be done on samples ordered from “medical institutions designated with outpatient facility for Japanese returnees and potential contacts” and “medical institutions recognized by the prefectures to have an equivalent function as outpatient facility for Japanese returnees and potential contacts”.

Testing employing real-time RT-PCR is conducted partly in a biosafety level 3 laboratory incorporating advanced containment measures. This is in compliance with the method outlined in the “Pathogen Detection Manual 2019-nCoV” (National Institute of Infectious Diseases) that makes use of commercially-available reagents.

LSI Medience hopes for the early recovery of all afflicted patients and an early resolution to this public health emergency resulting from the novel coronavirus.

**Contact:**

E-mail : [NPA-LSIM-PR@nm.medience.co.jp](mailto:NPA-LSIM-PR@nm.medience.co.jp)